Changes in vascular endothelial growth factor (VEGF) after chemoendocrine therapy in breast cancer

European Journal of Gynaecological Oncology

Volumn 25, Issue 1, 2004, Pages 45-50

  Fersis, N ^a   Smyczek Gargya, B ^a   Armeanu, S ^a   Gagulic, E ^a   Pantic, L ^a   Relakis, K ^a   Friedrich, M ^b   Wallwiener, D ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

Angiopoietin 1; Breast cancer cells; Preoperative chemotherapy; Vascular endothelial growth factor

Indexed keywords

ANGIOPOIETIN 1; DOCETAXEL; DOXORUBICIN; EXEMESTANE; LETROZOLE; TAMOXIFEN; TAMOXIFEN CITRATE; VASCULOTROPIN;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER HORMONE THERAPY; CELL STRAIN MCF 7; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE REPRESSION; HUMAN; HUMAN CELL; PREOPERATIVE TREATMENT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANDROSTADIENES; ANGIOPOIETIN-1; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL LINE, TUMOR; DNA PRIMERS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; NITRILES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, NEOPLASM; TAMOXIFEN; TAXOIDS; TRIAZOLES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 0842306968     PISSN: 03922936     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Yoshiji H., Harris S. R., Thorgeirsson U. P.: "Vascular endothelial growth factor is essential for initial but not continued in vivo growth of human breast carcinoma cells". Cancer Res., 1997, 57, 3924.
2. Stratmann A., Acker T., Burger A. M., Amann K., Risau W., Plate K. H.: "Differential inhibition of tumor angiogenesis by tie2 and vascular endothelial growth factor receptor-2 dominant-negative receptor mutants". Int. J. Cancer, 2001, 91, 273.
3. Yamamoto Y., Toi M., Kondo S., Matsumoto T., Suzuki H., Kitamura M. et al.: "Concentrations of vascular endothelial growth factor in the sera of normal controls and cancer patients". Clin. Cancer Res., 1996, 2, 821.
4. Foekens J. A., Peters H. A., Grebenchhtchikov N., Look M. P., Meijer-van Gelder M. E. et al.: "High tumor levels of vascular endothelial growth factor predict poor response to systemic therapy in advanced breast cancer". Cancer Res., 2001, 61, 5407.
5. Liu W., Ahmad S. A., Reinmuth N., Shaheen R. M., Jung Y. D., Fan F., Ellis L. M.: "Endothelial cell survival and apoptosis in the tumor vasculature". Apoposis, 2000, 5, 323.
6. Hayes A. J., Huang W. Q., Yu J., Maisonpierre P. C., Liu A., Kern F. G. et al.: "Expression and function of angiopoietin-1 in breast cancer". Br. J. Cancer, 2000, 83, 1154.
7. Tian S., Hayes A. J., Metheny-Barlow L. J., Li L. Y.: "Stabilization of breast cancer xenograft tumor neovasculature by angiopoietin-1". Br. J. Cancer. 2002, 86, 645.
8. Greb R. R., Maier I., Wallwiener D., Kiesel L.: "Vascular endothelial growth factor A (VEGF-A) nRNA expression levels decrease after menopause in normal breast tissue but not in breast cancer lesions". Br. J. Cancer, 1999, 81, 225.
9. Hyder S. M., Nawaz Z., Chiappetta C., Stancel G. M.: " Identification of functional estrogen response elements in the gene coding for the potent angiogenic factor vascular endothelial growth factor". Cancer Res., 2000, 60, 3183.
10. McNamara D. A., Harmey J., Wang J. H., Kay J. H., Walsh T. N., Bouchier-Hayes D. J.: "Tamoxifen inhibits endothelial cell proliferation and attentuates VEGF-mediated angiogenesis and migration in vivo". Eur. J. Surg. Oncol., 2001, 27, 714.
11. Lau D. H., Xue L., Young L. J., Burke P. A., Cheung A. T.: "Paclitaxel (Taxol): an inhibitor of angiogenesis in a highly vascularized transgenic breast cancer". Cancer Biother. Radiopharm., 1999, 14, 31.
12. Klauber N., Parangi S., Flynn E., Hamel E., D'Amato R. J.: Inhibition of angiogenesis and breast cancer in mice by the microtubule inhibitors 2-methoxyestradiol and taxol". Cancer Res., 1997, 57, 81.
13. Makris A., Powles T. J., Kakolyris S., Dowsett M., Ashley S. E., Harris A. L.: "Reduction of angiogenesis after neoadjuvant chemoendocrine therapy in patients with operable breast carcinoma". Cancer, 1999, 85, 1996.
14. Deplanque G., Harris A. L.: "Anti-angiogenic agents: clinical trial design and therapies in development". Eur. J. Cancer, 2000, 36, 1713.
15. Falardeau P., Champagne P., Poyet P., Hariton C., Dupont E.: "Neovastat, a naturally occurring multifunctional antiangiogenic drug, in phase III clinical trial". Semin. Oncol., 2001, 28, 620.
16. Lissoni P., Fugamalli F., Malugani A., Ardizzoia A., Secondino S., Tancini G., Gardani G. S.: "Chemotherapy and angiogenesis in advanced cancer: vascular endothelial growth factor (VEGF) decline as predictor of disease control during taxol therapy in metastatic breast cancer". Int. J. Biol. Marker, 2000, 15, 308.
17. 2 and ß-estradiol induce VEGF in MCF-7 and MCF-7-5c cells: relationship to in vivo hypoxia". Breast Canc. Res., 2001, 67, 51.
18. Saaristo A., Karpanen T., Alitalo K.: "Mechanism of angiogenesis and their use in the inhibition of tumor growth and metastasis". Oncogene, 2000, 19, 6122.
19. Yao J., Xiong S., Klos K., Nguyen N., Grijalva R., Li P., Yu D.: "Multiple signaling pathways involved in activation of matrix metalloproteinase-9 (MMP-9) by heregulin-beta1 in human breast cancer cells". Oncogene, 2001, 20, 8066.
20. Kumar R., Yarmand-Bagheri R.: "The role of HER2 in angiogenesis". Semin. Oncol., 2001, 5, 27.
21. Merendino R. A., Gangemi S., Ruello A., Bene A., Losi E., Lonbardo G., Purello-Dambrosio F.: "Serum levels of interleukin-18 and sCAM-1 in patients affected by breast cancer: preliminary considerations". Int. J. Biol. Markers, 2001, 16, 126.
22. Zaks-Zilberman M., Zaks T. Z., Vogel S. N.: "Induction of proinflammatory and chemokine genes by lipopolysacchacharide and paclitaxel (Taxol) in murine and human breast cancer cell lines". Cytokine, 2001, 15, 156.
23. Ruohola J. K., Valve E. M., Karkkainen M. J., Joukov V., Alitalo K., Härkönen P. L.: "Vascular endothelial growth factors are differentially regulated by steroid hormones and antiestrogens in breast cancer cells". Mol. Cell. Endocrinol., 1999, 149, 29.
24. Grenman R., Laine K. M., Klemi P. J., Grenman S., Hayashida D. J. S., Joensuu H.: "Effects of the antiestrogen toremifene on growth of the human mammary carcinoma cell line MCF-7". J. Cancer Res. Clin. Oncol., 1991, 117, 223.
25. Grainger D. J., Metcalfe J. C.: "Tamoxifen: teaching an old drug new tricks". Nature Med., 1996, 2, 381.
26. Donovan D., Harmey J. H., Redmond H. P., Bouchier-Hayes D. J.: "Ascites revisited: a novel role for tamoxifen". Eur. J. Surg. Oncol., 1997, 23, 570.
27. Geisler J., Detre S., Berntsen H., Ottestad L., Lindtjorn B., Dowsett M., Lonning P. S.: "Influence of neoadjuvant anastrozole (Arimidex) on intratumoral estrogen levels and proliferation markers in patients with locally advanced breast cancer". Clin. Canc. Res., 2001, 7, 1230.
28. Hyder S. M., Stancel G. M., Chiappetta C., Murthy L., Boettger-Tong H. L., Makela S.: "Uterine expression of vascular endothelial growth factor is increased by estradiol and tamoxifen". Canc. Res., 1996, 56, 3954.
29. Schimmng R., Hunter N. R., Mason K. A., Milas L.: "Inhibition of tumor neo-angiogenesis and induction of apoptosis as properties of docetacel". Mund. Kiefer Gesichtschirur., 1999, 3, 210.
30. Currie M. J., Gunningham S. P., Han C., Scott P. A. E., Robinson B. A., Harris A. L., Fox S. B.: "Angiopoietin-1 is inversely regulated to thymidine phosphrylase expression in human breast cancer, indicating a role in vascular remodelling". Clin. Canc. Res., 2001, 7, 918.
31. Gabrilovich D. I., Chen H. L., Girgis K. R., Cunningham H. T., Meny G. M., Nadaf S. et al.: "Production of vascular endothelial growth factor by human tumor inhibits the functional maturation of dendritic cells". Nat. Med., 1996, 2. 1096.
32. Radmacher M. D., Simon R.: "Estimation of tamoxifen's efficacy for preventing the formation and growth of breast tumors". J. Natl. Cancer Inst., 2000, 92, 48.